Link between COVID-19 vaccine complication and rare ‘common cold’ blood disease

Shared fingerprints of anti-PF4 antibodies in VITT and VITT-like disorders after adenovirus infection. Credit: New England Journal of Medicine (2024). DOI: 10.1056/NEJMc2402592 New research led by Flinders University and international experts is expanding understanding of vaccine-induced immune thrombocytopenia and thrombosis (known as VITT). At the height of the COVID-19 pandemic in 2021, VITT emerged as a new disease following adenovirus vector-based vaccines—notably the Oxford-AstraZeneca vaccine. VITT was found to be caused by an unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4). In separate research Read More